Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics dismisses CohnReznick, appoints Deloitte as auditor

Neutral Impact 3 of 5 other Written later

Inhibikase Therapeutics, Inc. dismissed CohnReznick LLP as its independent registered public accounting firm effective immediately and appointed Deloitte & Touche LLP for fiscal 2026, both approved by the Audit Committee on August 21, 2026. The prior auditor's reports on the 2025 and 2024 financial statements contained no adverse opinion, disclaimer, or qualification, and the filing reports no disagreements with the former auditor. The filing also discloses one reportable event: a material weakness in internal control over financial reporting that CohnReznick flagged for fiscal 2024, which the company says was remediated by prior management.

Key points

  • CohnReznick LLP dismissed effective immediately; Audit Committee approved the change on August 21, 2026
  • Deloitte & Touche LLP appointed as independent auditor for the fiscal year ending December 31, 2026
  • CohnReznick reported a material weakness in internal control over financial reporting during fiscal 2024, disclosed in the 10-Q for the quarter ended June 30, 2024
  • CohnReznick's response letter, dated August 26, 2026, is filed as Exhibit 16.1

The filing

CompanyInhibikase Therapeutics, Inc. (IKT)
Form8-K, current report
Filed with the SECAug 26, 2026, 4:05 PM ET
Accession number0001193125-26-368296

Items reported: 4.01 Auditor Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.